Publications by authors named "P C Will"

Background: Malignant tumors release growth factors, promoting lymphangiogenesis in primary tumors and draining sentinel lymph nodes, ultimately facilitating lymph node metastasis. As a malignant lymphatic tumor entity, lymphangiosarcomas are characterized by low survival rates and limited treatment options. The transcription factor SOX18 plays a crucial role in both lymphatic endothelial cell differentiation and cancer-induced lymphangiogenesis.

View Article and Find Full Text PDF

Background: The high incidence of vascular and lymphatic metastasis is closely associated with poor prognosis and mortality in cancer. Finding effective inhibitors to prevent pathological angiogenesis and lymphangiogenesis relies on appropriate in vivo models. The chick embryo chorioallantoic membrane (CAM) is formed by the fusion of the chorion and allantois during embryonic development.

View Article and Find Full Text PDF

Background: Lymphedema microsurgery is an emerging treatment modality, with dissimilar long-term outcomes. One of the main technical challenges in lymphatic microsurgery is the identification and availability of suitable donor vessels for anastomosis. Tissue engineering using biomaterials has demonstrated promise in addressing vessel quality issues in other fields, but its application in microsurgery is still limited.

View Article and Find Full Text PDF
Article Synopsis
  • Secondary lymphoedema (SL) is a common complication of cancer treatment, requiring careful diagnosis through techniques like MR lymphography and ICG lymphography for effective management.
  • The systematic review highlights the superiority of complex physical decongestion therapy (CPE) over other methods and demonstrates the positive outcomes of (super)microsurgical techniques in reducing symptoms and improving quality of life.
  • Ongoing conservative therapy and regular re-evaluation are crucial for patients with SL, particularly those at high risk or experiencing worsening symptoms.
View Article and Find Full Text PDF

Background: Secondary lymphedema (SL) affects 120 million people globally, posing a lifelong burden for up to 37% of cancer survivors. Chronic inflammation and progressive fibrosis are key drivers of SL, yet detailed characterization of immune cell subpopulations across lymphedema stages is lacking. This study aimed to investigate the immunologic profile of lymphedematous skin and its association with extracellular matrix changes, which could serve as clinical biomarkers or therapeutic targets.

View Article and Find Full Text PDF